ACCO Brands Corporation
NYSE:ACCOBusiness Equipment & Supplies
+$0.05 today
- Market cap
- $517.11M
- Beta
- 1.21
- P/E (TTM)
- 4.9
- EPS (TTM)
- $0.80
- Dividend yield
- 7.70%
Volume 1.77M
Average 1.07M
ACCO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
ACCO Brands CorporationNYSE: ACCO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $106.6M fell 0.4% year over year, behind the +237.1% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -45.2% a year.
Context
- Accounts receivables amounted to 0.3% of revenue in FY2025, down 2.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -0.4% toward the trailing-twelve-month pace of +237.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 5.2M USD
- Year-over-year change
- -88.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.2M | -88.0% |
| FY2024 | 2024-12-31 | 43.3M | +212.2% |
| FY2023 | 2023-12-31 | (38.6M) | -222.2% |
| FY2022 | 2022-12-31 | 31.6M | +140.7% |
| FY2021 | 2021-12-31 | (77.6M) | — |
Accounts Receivables vs competitors
How ACCO compares with its peers on the latest reported figures
- ACCO's LTM Mar 2026 accounts receivables of $4.8M is the 7th largest of the 11 companies compared; the peer median is $180.3K.
- Its year-over-year change of +237.1% is the highest of 11, against a peer median of -85.7%.
- Accounts receivables amounts to 0.3% of revenue for ACCO, versus a peer median of 0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.1M | -82.8% | — | 0.9% | |
| LTM Mar 2026 | $10.3M | -53.8% | -37.0% | 0.5% | |
| LTM Mar 2026 | $9.97M | -194.7% | -47.5% | 1.8% | |
| LTM Mar 2026 | $6.68M | -284.5% | — | 1.8% | |
| LTM Apr 2026 | $6.34M | -168.3% | — | 1.5% | |
| LTM Mar 2026 | $5.3M | +65.6% | -40.4% | 0.3% | |
| LTM Mar 2026 | $4.8M | +237.1% | -45.2% | 0.3% | |
| LTM Mar 2026 | $3.93M | +74.2% | — | 6.2% | |
| LTM Mar 2026 | $3.28M | -78.6% | — | 0.9% | |
| LTM Feb 2026 | $1.09M | -88.6% | — | 0.3% | |
SBCSBC Medical Group Holdings Incorporated | LTM Mar 2026 | $727.39K | -230.0% | — | 0.4% |
| Peer median (excluding ACCO) | $180.3K | -85.7% | -40.4% | 0.9% | |
Competitors are the stored peer set for ACCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 101.9M | (13.2M) | (21.8M) | (101.6M) | 41.3M |
| Depreciation & Amortization | 85.7M | 79.4M | 76.1M | 73.1M | 72.8M |
| Deferred Income Tax | (21M) | 1.3M | (20.1M) | (6.9M) | (3.5M) |
| Stock-Based Compensation | 15.2M | 9.5M | 14.8M | 11.9M | 11.5M |
| Change in Working Capital | (50.8M) | (79M) | (12.5M) | 4.5M | (48.9M) |
| Accounts Receivables | (77.6M) | 31.6M | (38.6M) | 43.3M | 5.2M |
| Inventory | (131.8M) | 23.2M | 85.5M | 38.3M | 1.1M |
| Accounts Payables | 131.2M | (66M) | (68M) | (6.3M) | 10M |
| Other Working Capital | 27.4M | (67.8M) | 8.6M | (70.8M) | (65.2M) |
| Other Non-Cash Items | 28.6M | 79.6M | 92.2M | 167.2M | (4.5M) |
| Operating Cash Flow | 159.6M | 77.6M | 128.7M | 148.2M | 68.7M |
| Capital Expenditures | (21.2M) | (16.5M) | (13.8M) | (15.9M) | (17.9M) |
| Acquisitions (Net) | 15.4M | 7.2M | 0 | 0 | (10.1M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2.6M | 3.6M | 18.7M |
| Investing Cash Flow | (5.8M) | (9.3M) | (11.2M) | (12.3M) | (9.3M) |
| Debt Repayment | (102.9M) | 16.9M | (87.5M) | (74.7M) | (33.7M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (19.4M) | (1.7M) | (15M) | (15.1M) |
| Dividends Paid | (25.8M) | (28.6M) | (28.5M) | (28.4M) | (27M) |
| Other Financing Activities | (18.5M) | (14.7M) | 0 | (4.5M) | (900K) |
| Financing Cash Flow | (147.2M) | (48.3M) | (117.7M) | (122.6M) | (76.7M) |
| Effect of Forex Changes | (2M) | 1M | 4.4M | (5.6M) | 7.6M |
| Net Change in Cash | 4.6M | 21M | 4.2M | 7.7M | (9.7M) |
| Free Cash Flow | 138.4M | 61.1M | 114.9M | 132.3M | 50.8M |
ACCO Brands Corporation
NYSE:ACCO
Intrinsic Alpha fair value
Locked
Current Price
$5.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.